<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Lansoprazole</strong></td></tr><tr><th>Accession Number</th><td><strong>DB00448</strong>&#160; (APRD00077)</td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved, investigational</td></tr><tr><th>Description</th><td><p>Lansoprazole is a proton pump inhibitor which prevents the stomach from producing acid. It is manufactured by <span class="caps">TAP</span> Pharmaceutical Products. Lansoprazole has been marketed for many years and is one of several PPI&#8217;s available.</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB00448/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB00448/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00448.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00448.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00448.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00448.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00448.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB00448">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="synonyms"><thead><th>Synonym</th><th>Language</th><th>Code</th></thead><tbody><tr><td>Lansoprazol</td><td>German/Spanish</td><td>INN</td></tr><tr><td>Lansoprazole</td><td><span class="wishart wishart-not-available">Not Available</span></td><td>INN, BAN, USAN</td></tr><tr><td>Lansoprazolum</td><td>Latin</td><td>INN</td></tr></tbody></table></td></tr><tr><th>Salts</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Agopton</td><td>Takeda</td></tr><tr><td>Bamalite</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Lansoloc</td><td>Cipla Medpro</td></tr><tr><td>Lanzol</td><td>Cipla</td></tr><tr><td>Lanzopral</td><td>Pharma Investi</td></tr><tr><td>Lanzopran</td><td>Ranbaxy</td></tr><tr><td>Limpidex</td><td>Sigma-Tau</td></tr><tr><td>Monolitum</td><td>Salvat</td></tr><tr><td>Ogast</td><td>Takeda</td></tr><tr><td>Ogastro</td><td>Abbott</td></tr><tr><td>Opiren</td><td>Almirall</td></tr><tr><td>Prevacid</td><td>Novartis</td></tr><tr><td>Prevacid 24HR</td><td>Novartis</td></tr><tr><td>Prevacid IV</td><td>Novartis</td></tr><tr><td>Prevacid Solutab</td><td>Novartis</td></tr><tr><td>Prosogan</td><td>Takeda</td></tr><tr><td>Takepron</td><td>Takeda</td></tr><tr><td>Ulpax</td><td>Hormona</td></tr><tr><td>Zoprol</td><td>Toprak</td></tr><tr><td>Zoton</td><td>Pfizer</td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Categories</th><td><ul><li><a href="/mesh/enzyme-inhibitors">Enzyme Inhibitors</a></li>
<li><a href="/mesh/anti-ulcer-agents">Anti-Ulcer Agents</a></li>
<li><a href="/mesh/proton-pump-inhibitors">Proton Pump Inhibitors</a></li>
<li><a href="/mesh/anti-infective-agents">Anti-Infective Agents</a></li></ul></td></tr><tr><th>CAS number</th><td>103577-45-3</td></tr><tr><th>Weight</th><td>Average: 369.361<br>Monoisotopic: 369.075882012</td></tr><tr><th>Chemical Formula</th><td>C<sub>16</sub>H<sub>14</sub>F<sub>3</sub>N<sub>3</sub>O<sub>2</sub>S</td></tr><tr><th>InChI Key</th><td>MJIHNNLFOKEZEW-UHFFFAOYSA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C16H14F3N3O2S/c1-10-13(20-7-6-14(10)24-9-16(17,18)19)8-25(23)15-21-11-4-2-3-5-12(11)22-15/h2-7H,8-9H2,1H3,(H,21,22)</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">2-({[3-methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]methane}sulfinyl)-1H-1,3-benzodiazole</div></td></tr><tr><th>SMILES</th><td><div class="wrap">CC1=C(OCC(F)(F)F)C=CN=C1CS(=O)C1=NC2=CC=CC=C2N1</div></td></tr><tr><th>Mass Spec</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Heterocyclic Compounds</td></tr><tr><th>Class</th><td>Benzimidazoles</td></tr><tr><th>Subclass</th><td>Sulfinylbenzimidazoles</td></tr><tr><th>Direct parent</th><td>Sulfinylbenzimidazoles</td></tr><tr><th>Alternative parents</th><td>Alkyl Aryl Ethers; Pyridines and Derivatives; Benzene and Substituted Derivatives; Imidazoles; Sulfoxides; Polyamines; Alkyl Fluorides; Organofluorides</td></tr><tr><th>Substituents</th><td>alkyl aryl ether; benzene; pyridine; azole; imidazole; sulfoxide; ether; polyamine; organofluoride; organohalogen; alkyl halide; alkyl fluoride; organonitrogen compound</td></tr><tr><th>Classification description</th><td>This compound belongs to the sulfinylbenzimidazoles. These are polycyclic aromatic compounds containing a sulfinyl group attached at the position 2 of a benzimidazole moiety.</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>For the treatment of acid-reflux disorders (GERD), peptic ulcer disease, H. pylori eradication, and prevention of gastroinetestinal bleeds with NSAID use.</td></tr><tr><th>Pharmacodynamics</th><td>Lansoprazole, an acid proton-pump inhibitor similar to omeprazole, is used as an untiulcer drug in the treatment and maintenance of healing of duodenal or gastric ulcers, erosive and reflux esophagitis, NSAID-induced ulcer, Zollinger-Ellison syndrome, and Barrett's esophagus. Lansoprozole is active against <i>Helicobacter pylori</i>. The plasma elimination half-life of lansoprazole does not reflect its duration of suppression of gastric acid secretion. Thus, the plasma elimination half-life is less than two hours, while the acid inhibitory effect lasts more than 24 hours.</td></tr><tr><th>Mechanism of action</th><td>Lansoprazole belongs to a class of antisecretory compounds, the substituted benzimidazoles, that do not exhibit anticholinergic or histamine H<sub>2</sub>-receptor antagonist properties, but rather suppress gastric acid secretion by specific inhibition of the (H<sup>+</sup>,K<sup>+</sup>)-ATPase enzyme system at the secretory surface of the gastric parietal cell. Because this enzyme system is regarded as the acid (proton) pump within the parietal cell, Lansoprazole has been characterized as a gastric acid-pump inhibitor, in that it blocks the final step of acid production. This effect is dose-related and leads to inhibition of both basal and stimulated gastric acid secretion irrespective of the stimulus.</td></tr><tr><th>Absorption</th><td>The absorption of lansoprazole is rapid, with mean C<sub>max</sub> occurring approximately 1.7 hours after oral dosing, and relatively complete with absolute bioavailability over 80%.</td></tr><tr><th>Volume of distribution</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Protein binding</th><td>97%</td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>Hepatic. Two metabolites have been identified in measurable quantities in plasma (the hydroxylated sulfinyl and sulfone derivatives of lansoprazole). These metabolites have very little or no antisecretory activity. Lansoprazole is thought to be transformed into two active species which inhibit acid secretion by (H<sup>+</sup>,K<sup>+</sup>)-ATPase within the parietal cell canaliculus, but are not present in the systemic circulation.</p><table class="table-standard table-condensed" id="experimental-properties"><thead><tr><th>Substrate</th><th>Enzymes</th><th colspan="2">Product</th></tr></thead><tbody><tr><td>Lansoprazole</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0003536" target="_blank">Cytochrome P450 2C19</a></li>
<li><a href="/biodb/bio_entities/BE0002638" target="_blank">Cytochrome P450 3A4</a></li>
<li><a href="/biodb/bio_entities/BE0002793" target="_blank">Cytochrome P450 2C9</a></li></ul></td><td><a href="/metabolites/DBMET00183">5-Hydroxylansoprazole</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/184">Details</a></td></tr><tr><td>Lansoprazole</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0002638" target="_blank">Cytochrome P450 3A4</a></li></ul></td><td><a href="/metabolites/DBMET00184">Lansoprazole sulfone</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/185">Details</a></td></tr></tbody></table></td></tr><tr><th>Route of elimination</th><td>Following single-dose oral administration of PREVACID, virtually no unchanged lansoprazole was excreted in the urine. In one study, after a single oral dose of 14C-lansoprazole, approximately one-third of the administered radiation was excreted in the urine and two-thirds was recovered in the feces. This implies a significant biliary excretion of the lansoprazole metabolites.</td></tr><tr><th>Half life</th><td>1.5 (&#177; 1.0) hours</td></tr><tr><th>Clearance</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Toxicity</th><td>Symptoms of overdose include abdominal pain, nausea and diarrhea.</td></tr><tr><th>Affected organisms</th><td><ul><li>Humans and other mammals</li></ul></td></tr><tr><th>Pathways</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Effects</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="snp-fx"><thead><tr><th>Interacting Gene/Enzyme</th><th>SNP RS ID</th><th>Allele name</th><th>Defining change</th><th>Effect</th><th>Reference(s)</th></tr></thead><tbody><tr><td>Cytochrome P450 2C19<br>Gene symbol: CYP2C19<br>UniProt: <a class="wishart-link-out" href="http://www.uniprot.org/uniprot/P33261" target="_blank">P33261 <span class="glyphicon glyphicon-new-window"> </span></a></td><td><a class="wishart-link-out" href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=rs4244285" target="_blank">rs4244285 <span class="glyphicon glyphicon-new-window"> </span></a></td><td>CYP2C19*2</td><td>A Allele, homozygote</td><td>Poor metabolizer, lower dose requirement, improved drug efficacy</td><td><span class="citation"><a class="pubmed-link wishart-link-out" data-toggle="tooltip" href="http://www.ncbi.nlm.nih.gov/pubmed/9867757" target="_blank" title="Furuta T, Ohashi K, Kamata T, Takashima M, Kosuge K, Kawasaki T, Hanai H, Kubota T, Ishizaki T, Kaneko E: Effect of genetic differences in omeprazole metabolism on cure rates for Helicobacter pylori infection and peptic ulcer. Ann Intern Med. 1998 Dec 15;129(12):1027-30.">9867757 <span class="glyphicon glyphicon-new-window"> </span></a></span></td></tr><tr><td>Cytochrome P450 2C19<br>Gene symbol: CYP2C19<br>UniProt: <a class="wishart-link-out" href="http://www.uniprot.org/uniprot/P33261" target="_blank">P33261 <span class="glyphicon glyphicon-new-window"> </span></a></td><td><a class="wishart-link-out" href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=rs4986893" target="_blank">rs4986893 <span class="glyphicon glyphicon-new-window"> </span></a></td><td>CYP2C19*3</td><td>A Allele, homozygote</td><td>Poor metabolizer, lower dose requirement, improved drug efficacy</td><td><span class="citation"><a class="pubmed-link wishart-link-out" data-toggle="tooltip" href="http://www.ncbi.nlm.nih.gov/pubmed/9867757" target="_blank" title="Furuta T, Ohashi K, Kamata T, Takashima M, Kosuge K, Kawasaki T, Hanai H, Kubota T, Ishizaki T, Kaneko E: Effect of genetic differences in omeprazole metabolism on cure rates for Helicobacter pylori infection and peptic ulcer. Ann Intern Med. 1998 Dec 15;129(12):1027-30.">9867757 <span class="glyphicon glyphicon-new-window"> </span></a></span></td></tr></tbody></table></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              +
        </td>
        <td>0.9972</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              +
        </td>
        <td>0.7007</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              +
        </td>
        <td>0.8866</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Non-substrate
        </td>
        <td>0.547</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Inhibitor
        </td>
        <td>0.5357</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.8692</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Inhibitor
        </td>
        <td>0.5521</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.7826</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-substrate</td>
        <td>0.8659</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Substrate</td>
        <td>0.6771</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Inhibitor</td>
        <td>0.9106</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9071</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Inhibitor</td>
        <td>0.8932</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Inhibitor</td>
        <td>0.8993</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Inhibitor</td>
        <td>0.7959</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>High CYP Inhibitory Promiscuity</td>
        <td>0.8768</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          Non AMES toxic 
        </td>
        <td>
            0.5858
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.7944
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Not ready biodegradable 
        </td>
        <td>
            1.0
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          1.8997 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Weak inhibitor 
        </td>
        <td>
            0.8777
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Non-inhibitor 
        </td>
        <td>
            0.8734
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><ul><li>Matrix laboratories ltd</li>
<li>Teva pharmaceuticals usa</li>
<li>Takeda pharmaceuticals north america inc</li>
<li>Novartis consumer health inc</li>
<li>Sandoz inc</li></ul></td></tr><tr><th>Packagers</th><td><ul><li><a href="http://www.abbott.com">Abbott Laboratories Ltd.</a></li>
<li>Advanced Pharmaceutical Services Inc.</li>
<li><a href="http://www.aqpharmaceuticals.com">AQ Pharmaceuticals Inc.</a></li>
<li><a href="http://orders.a-smeds.com">A-S Medication Solutions LLC</a></li>
<li><a href="http://www.cardinal.com">Cardinal Health</a></li>
<li><a href="http://www.caremark.com">Caremark LLC</a></li>
<li>Direct Pharmaceuticals Inc.</li>
<li><a href="http://www.drxdispensing.com">Dispensing Solutions</a></li>
<li><a href="http://hjharkinscompanyinc.com">H.J. Harkins Co. Inc.</a></li>
<li>Heartland Repack Services LLC</li>
<li><a href="http://www.innoviantpharmacy.com">Innoviant Pharmacy Inc.</a></li>
<li><a href="http://www.inventiahealthcare.com">Inventia Healthcare Pvt Ltd.</a></li>
<li>Lake Erie Medical and Surgical Supply</li>
<li><a href="http://www.mckesson.com">Mckesson Corp.</a></li>
<li><a href="http://www.medisca.com">Medisca Inc.</a></li>
<li><a href="http://www.unitdosesupply.com">Murfreesboro Pharmaceutical Nursing Supply</a></li>
<li><a href="http://www.mylan.com">Mylan</a></li>
<li><a href="http://www.novartis.com">Novartis AG</a></li>
<li><a href="http://www.nucarerx.com">Nucare Pharmaceuticals Inc.</a></li>
<li><a href="http://www.patheon.com">Patheon Inc.</a></li>
<li><a href="http://www.pdrx.com">PD-Rx Pharmaceuticals Inc.</a></li>
<li>Pharmaceutical Utilization Management Program VA Inc.</li>
<li><a href="http://www.physicianstotalcare.com">Physicians Total Care Inc.</a></li>
<li><a href="http://www.preferredpharmaceuticals.com">Preferred Pharmaceuticals Inc.</a></li>
<li>Prepackage Specialists</li>
<li>Promex Medical Inc.</li>
<li>Redpharm Drug</li>
<li>Resource Optimization and Innovation LLC</li>
<li><a href="http://www.sandoz.ca">Sandoz</a></li>
<li><a href="http://www.southwoodhealthcare.com">Southwood Pharmaceuticals</a></li>
<li><a href="http://statrxusa.exporterus.com">Stat Rx Usa</a></li>
<li><a href="http://www.takeda.com">Takeda Pharmaceutical Co. Ltd.</a></li>
<li>TAP Pharmaceuticals</li>
<li><a href="http://www.tevapharm.com">Teva Pharmaceutical Industries Ltd.</a></li>
<li><a href="http://www.udllabs.com">UDL Laboratories</a></li>
<li>Va Cmop Dallas</li>
<li>Vangard Labs Inc.</li></ul></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Capsule, delayed release</td><td>Oral</td><td></td></tr><tr><td>Tablet, delayed release</td><td>Oral</td><td></td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><ul><li><a data-no-turbolink="true" href="/spectra/spectra/nmr_one_d/2017">1H NMR Spectrum</a></li>
<li><a data-no-turbolink="true" href="/spectra/spectra/ms_ms/2439">MS/MS Spectrum Quattro_QQQ 10</a></li>
<li><a data-no-turbolink="true" href="/spectra/spectra/ms_ms/2440">MS/MS Spectrum Quattro_QQQ 25</a></li>
<li><a data-no-turbolink="true" href="/spectra/spectra/ms_ms/2441">MS/MS Spectrum Quattro_QQQ 40</a></li>
<li><a data-no-turbolink="true" href="/spectra/spectra/nmr_two_d/1952">[1H,13C] 2D NMR Spectrum</a></li></ul></td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB01072">Atazanavir</a></td><td>This gastric pH modifier decreases the levels/effects of atazanavir</td></tr><tr><td><a href="/drugs/DB06616">Bosutinib</a></td><td>Concomitant lansoprazole (PPI) decreased bosutinib Cmax by 46% and AUC by 26% compared to bosutinib alone. Consider using short-acting antacids or H2 blockers instead of PPIs to avoid a reduction in bosutinib exposure. Separate antacid or H2 blocker dosing and BOSULIF dosing by more than 2 hours. </td></tr><tr><td><a href="/drugs/DB01066">Cefditoren</a></td><td>Proton pump inhibitors such as lansoprazole may decrease the serum concentration of cefditoren. If possible, avoid use of cefditoren with proton pump inhibitors (PPIs). Consider alternative methods to minimize/control acid reflux (eg, diet modification) or alternative antimicrobial therapy if use of PPIs can not be avoided.</td></tr><tr><td><a href="/drugs/DB00758">Clopidogrel</a></td><td>Lansoprazole may decrease serum concentrations of the active metabolite(s) of clopidogrel. Due to the possible risk for impaired clopidogrel effectiveness with this combination, clinicians should carefully consider the need for concurrent lansoprazole therapy in patients receiving clopidogrel. Monitor response to clopidogrel closely when using clopidogrel with lansoprazole. Whether there are differences among individual proton pump inhibitors is unclear. Other acid-lowering therapies (e.g., H2-receptor antagonists, antacids, etc.) do not appear to share this interaction with clopidogrel. </td></tr><tr><td><a href="/drugs/DB00467">Enoxacin</a></td><td>Lansoprazole may decrease the absorption of enoxacin.</td></tr><tr><td><a href="/drugs/DB00224">Indinavir</a></td><td>Omeprazole decreases the absorption of indinavir</td></tr><tr><td><a href="/drugs/DB01167">Itraconazole</a></td><td>The proton pump inhibitor, lansoprazole, may decrease the absorption of itraconazole.</td></tr><tr><td><a href="/drugs/DB01026">Ketoconazole</a></td><td>The proton pump inhibitor, lansoprazole, may decrease the absorption of ketoconazole.</td></tr><tr><td><a href="/drugs/DB06209">Prasugrel</a></td><td>Lansoprazole is a CYP2C19 substrate which decreases AUC and Cmax of prasugrel. Despite these decreases, there was no significant reduction of inhibition of platelet aggregation. </td></tr><tr><td><a href="/drugs/DB08864">Rilpivirine</a></td><td>Proton-pump inhibitors increase gastric pH which causes a decrease in the exposure of rilpivirine thus reducing efficacy. </td></tr><tr><td><a href="/drugs/DB00364">Sucralfate</a></td><td>Sucralfate decreases the effect of lansoprazole</td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><ul><li>Avoid alcohol.</li>
<li>Food reduces bioavailabilty, but this has very little clinical impact.</li>
<li>Take 30-60 minutes before meals.</li></ul></td></tr></tbody></table>